Atypical Metatarsal Fractures: Report of Five Clinical Cases

Abstract

Atypical fractures are well elucidated when they occur in the femur and are related to the use of bisphosphonates. Prolonged therapy with this drug leads to excessive suppression of bone remodeling, which makes the bone more brittle. In general, they are caused by minimal trauma or are atraumatic. This type of fracture is also reported in other bony sites, such as the metatarsus. Some reports and studies on atypical metatarsal fractures have been published, but further investigations are required to better understand this type of fracture and establish the proper diagnosis, treatment and conduct.

The present study is a report of five cases of patients who presented metatarsal fractures during therapy with bisphosphonates. All patients were female, had osteoporosis as a preexisting disease, were taking bisphosphonates, presented fractures that were either atraumatic or caused by minimal trauma, and the imaging examination showed a transverse meta-diaphyseal fracture of the fifth metatarsal shaft with thickening of the lateral cortex, image characteristics similar to the criteria used by the American Society for Bone and Mineral Research (ASMBR) to define atypical femur fractures.

Keywords
biphosphonates; femoral fractures; fractures, bone; metatarsus; osteoporosis

Resumo

Fraturas atípicas são bem elucidadas quando ocorrem no fêmur e tem relação com o uso de bifosfonatos. A terapia prolongada com esse medicamento leva a uma supressão excessiva do remodelamento ósseo, o que torna o osso mais quebradiço. Em geral, são fraturas atraumáticas ou causadas por trauma mínimo. Este tipo de fratura é também relatada em outros sítios ósseos, como o metatarso. Alguns relatos e estudos referentes às fraturas atípicas de metatarso já foram publicados, mas outras investigações são necessárias para que essa fraturas sejam mais bem compreendidas e recebam o devido diagnóstico, tratamento e conduta.

No presente trabalho, relatam-se cinco casos de pacientes que apresentaram fratura de metatarso durante terapia com bifosfonatos. Todos os pacientes eram do sexo feminino, tinham osteoporose como doença pré-existente, faziam uso de bifosfonatos, apresentaram fraturas atraumáticas ou causadas por trauma mínimo, e o exame de imagem revelou fratura metadiafisária transversa de eixo de quinto metatarso com espessamento do córtex lateral, características de imagem semelhantes aos critérios utilizados pela American Society for Bone and Mineral Research (ASMBR) para definir fraturas atípicas de fêmur.

Palavras-chave
bifosfonatos; fraturas do fêmur; fraturas ósseas; metatarso; osteoporose

Introduction

Atypical fractures due to prolonged use of bisphosphonates in the treatment of osteoporosis were first reported in the 2000s.¹ Those that occur in the femur are well defined by the American Society for Bone and Mineral Research (ASMBR); however, reports² indicate that they can also occur in other bones, such as the metatarsus.

Shane et al.² elucidated the criteria for atypical femur fractures: association with no or minimal trauma; prodromal symptoms; fracture line originating in the lateral cortex and substantially transverse in its orientation, which may also become oblique as it progresses medially through the femur; complete fractures extend through both corticals and may be associated with a medial tip, while incomplete fractures only involve the lateral cortical; fractures that are non-comminuted or minimally comminuted; and the presence of periosteal or endosteal thickening, which appears radiologically as a "beak" in the lateral cortex of the fracture.²

Atypical fractures of other bones besides the femur, such as the pelvis, humerus, tibia, and metatarsus have been reported in other studies.³–⁶ In the first epidemiological study on metatarsal fractures,⁶ published in 2020, the authors concluded that the use of bisphosphonates is associated to an increased risk of metatarsal fractures, but not to the duration of drug use.

Reports on atypical metatarsal fractures, as well as studies that provide guidance on diagnosis and management, are scarce. The aim of the present study is to describe five cases of this type of fracture in patients with osteoporosis undergoing bisphosphonate therapy.

Clinical Cases

The present study was approved by the institutional Ethics in Research Committee; it was included in Plataforma Brasil (CAAE- 50365521.3.0000.5086), and the informed consent form was signed by the participants.

The five clinical cases are summarized in Table 1 to elucidate the most relevant information regarding atypical metatarsal fractures.

Table 1
Patients and data on atypical metatarsal fractures

Patient	Age in years	Atraumatic or minimal trauma	Imaging study	Preexisting disease	Bisphosphonate used (therapy duration)
I	77	Atraumatic	Transverse metadiaphyseal fracture of the fifth metatarsal shaft with thickening of the lateral cortex	Osteoporosis	Risedronate sodium (> 7 years)
II	51	Atraumatic	Transverse metadiaphyseal fracture of the fifth metatarsal shaft with thickening of the lateral cortex	Osteoporosis	Ibandronate sodium (> 5 years)
III	77	Atraumatic	Transverse metadiaphyseal fracture of the fifth metatarsal shaft with thickening of the lateral cortex	Osteoporosis	Alendronate sodium (10 years)
IV	65	Atraumatic	Transverse metadiaphyseal fracture of the fifth metatarsal shaft with thickening of the lateral cortex	Osteoporosis	Alendronate sodium (5 years)
V	66	Minimal trauma	Transverse metadiaphyseal fracture of the fifth metatarsal shaft with thickening of the lateral cortex	Osteoporosis	Zoledronic acid (2 years); previous use of alendronate sodium (7 years)

All patients were female, and anteroposterior and oblique radiographs revealed transverse metadiaphyseal fracture of the fifth metatarsal axis with thickening of the lateral cortex, as shown in Fig. 1 regarding patient V.

Fig. 1
Anteroposterior and oblique radiographs of the right foot.

Discussion

The patients were aged between 51 and 77 years; they all had osteoporosis as the underlying condition, and the average use of bisphosphonates to treat the disease until the moment of the fracture was of 7.2 years.

In every case, the fracture had transverse metadiaphyseal presentation of the axis of the fifth metatarsal with thickening of the lateral cortex, features similar to the criteria used by the ASMBR to define atypical femur fractures.²

There is concern that prolonged therapy leads to excessive suppression of bone remodeling,⁷ which makes bones more brittle and causes the buildup of microdamage, increasing the risk of fractures.⁷

West et al.⁶ concluded that the risk of metatarsal fracture among postmenopausal women taking therapeutic bisphosphonates was higher with younger age, non-Hispanic white ethnicity, and history of diabetes, rheumatoid arthritis, fracture, and treatment with glucocorticoids.

The lack of criteria to define atypical metatarsal fractures makes the diagnosis difficult, and they may be considered simple stress fractures, as occurs in the case of atypical femoral fractures,⁸ or the relationships involving fractures and comorbidities and fractures and the concomitant use of other medications may not noted, as indicated in the ASMBR criteria for atypical femur fractures.²

Therapeutic suspension may be considered for atypical fractures; however, in the case of atypical femur fractures, Brown et al.⁹ indicated that it should only be performed in specific situations. Correspondingly, the management of patients with atypical metatarsal fractures may have similar indications that should be properly studied and elucidated. In the present study, we recommended that all patients discontinue the use of bisphosphonates and switch to another drug line, in addition to undergoing conservative treatment, which showed good evolution in four of the cases, one of which was still under treatment until the submission of the study.

Atypical metatarsal fractures need further studies so that the diagnosis and management are better delineated. As suggested by Unnanuntana et al.¹⁰ regarding atypical fractures of the femur, studies on atypical metatarsal fractures that focus on bone histomorphometry and biomechanical properties should be carried out for a deeper understanding of the relationship between bisphosphonates and this type of fracture.

• Financial Support
  The authors declare that they have received no financial support from public, commercial, or non-profit sources.
• Study carried out at the School of Medicine at Universidade Federal do Maranhão, São Luís, MA, Brazil.

References

• ¹
  Toro G, Ojeda-Thies C, Calabrò G, et al. Management of atypical femoral fracture: a scoping review and comprehensive algorithm. BMC Musculoskelet Disord 2016;17:227
• ²
  Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29(01):1–23
• ³
  Corrarino JE. Bisphosphonates and atypical femoral fractures. J Nurse Pract 2015;11(04):389–396
• ⁴
  Bissonnette L, April PM, Dumais R, Boire G, Roux S. Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: a case report. Bone 2013;56(02):406–409
• ⁵
  Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendro-nate. Geriatrics 2006;61(01):31–33
• ⁶
  West TA, Pollard JD, Chandra M, et al. The Epidemiology of Metatarsal Fractures Among Older Females With Bisphosphonate Exposure. J Foot Ankle Surg 2020;59(02):269–273
• ⁷
  Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90(03):1897–1899
• ⁸
  Marshall RA, Mandell JC, Weaver MJ, Ferrone M, Sodickson A, Khurana B. Imaging Features and Management of Stress, Atypical, and Pathologic Fractures. Radiographics 2018;38(07): 2173–2192
• ⁹
  Brown JP, Morin S, Leslie W, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician 2014;60(04):324–333
• ¹⁰
  Unnanuntana A, Saleh A, Mensah KA, Kleimeyer JP, Lane JM. Atypical femoral fractures: what do we know about them?: AAOS Exhibit Selection J Bone Joint Surg Am 2013;95(02): e8–e13, 1–13

Publication Dates

• Publication in this collection
  30 Sept 2024
• Date of issue
  2024

History

• Received
  05 Mar 2022
• Accepted
  27 Oct 2022